KAO JOHN E sold $4.1M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at $13.88 ($4.14M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Aug 10, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 298,000 shares for about $4.14M, executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a concrete insider liquidity event for ALHC, but it lacks accompanying fundamental updates.

03

What to watch

Traders may overreact to insider sales; the key is whether there are simultaneous company catalysts (earnings, guidance, contracts) not present in this filing.

Relevance 5/10Novelty 5/10Timing: filed on 2026-08-10, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

CEO John E. Kao sold 298,000 shares of Alignment Healthcare on 2026-08-10 at $13.8818 via a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape and any concurrent company-specific catalysts.

Evidence & confidence

Form 4 shows an open-market sale under a pre-arranged 10b5-1 plan, reducing the signal strength versus discretionary selling. The article provides transaction size and price but no new operating or guidance information.

Market effects

No sector-wide implications; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may be routine liquidity management and not a bearish signal.

Key entities

  • Alignment Healthcare, Inc.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • John E. Kao

    CEO and director who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.